Related Experiment Video
Updated: Feb 17, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
New targets for antipsychotics
1Section of Neurochemical Imaging, Institute of Psychiatry, Denmark Hill, London, SE5 8AF, UK.
Abstract:
Atypical antipsychotic drugs have a favorable side effect profile compared with older neuroleptics. Clozapine exhibits superior clinical efficacy in resistant schizophrenia. The neurochemical profile of these atypical agents suggests two distinct strategies in the development of novel antipsychotic drugs. Better-targeted dopaminergic agents may avoid the side effects associated with profound D2 receptor blockade. Current approaches include D3 receptor antagonists and drugs combining partial agonist activity at dopamine autoreceptors with conventional D2 antagonism. The D1 receptor may be a potential target for improving cognitive function in schizophrenia. Secondly drugs acting at glutamate (NMDA) and serotonin (5-HT(2A), 5-HT(1A), 5-HT(2C), 5-HT(3)) receptors may offer improved treatment particularly against resistant schizophrenic symptoms, as well as improving the side effect profile of antipsychotic drugs. This research in receptor pharmacology is set in the context of the increasingly recognised importance of the clinical care for patients with first onset schizophrenia and recent developments in pharmacogenomics.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications
Antipsychotic Drugs: Typical and Atypical Agents
Psychosis and Antipsychotic Drugs: Overview
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Antidepressant Drugs: MAOIs and Other Agents

